Servier gets EU rights to Taiho's TAS-102

Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan) granted Servier (Neuilly-sur-Seine, France) an exclusive license to TAS-102 trifluridine/tipracil in the EU. An MAA for the therapy is under EMA review to treat refractory metastatic colorectal cancer (CRC).

Taiho will receive $40 million up front and would receive an additional $90 million if EMA approves the therapy. Taiho said it will retain rights to TAS-102 in North America and Asia, and is eligible for additional milestones and undisclosed royalties from European sales. ...